Vitrolife faces a tough H2 in 2025, and we expect this to continue during H1 2025. In short, Vitrolife is stepping up its investments in commercial capacity and sales during a period of softer organic growth. In Q2, the softer areas are the APAC regions and technologies, apart from pressure in FX (-8%) and discontinued EMEA business.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/